Barclays PLC Crispr Therapeutics Ag Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Barclays PLC holds 129,848 shares of CRSP stock, worth $5.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,848

Previous 129,848 -0.0%

Holding current value

$5.29 Million

Previous $6.1 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$44.62 - $62.75 $2.87 Million - $4.03 Million	64,228 Added 97.88%	129,848 $6.1 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $9.76 Million - $13 Million	-190,711 Reduced 74.4%	65,620 $3.54 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $3.44 Million - $5.05 Million	-56,634 Reduced 18.1%	256,331 $17.5 Million
Q4 2023 Feb 15, 2024	SELL	$38.62 - $72.18 $7.64 Million - $14.3 Million	-197,867 Reduced 38.73%	312,965 $19.6 Million
Q3 2023 Nov 07, 2023	BUY	$45.39 - $59.0 $6.25 Million - $8.12 Million	137,629 Added 36.88%	510,832 $23.2 Million
Q2 2023 Aug 03, 2023	BUY	$43.47 - $67.77 $497,470 - $775,559	11,444 Added 3.16%	373,203 $21 Million
Q1 2023 May 04, 2023	SELL	$41.0 - $56.12 $1.14 Million - $1.57 Million	-27,918 Reduced 7.16%	361,759 $16.4 Million
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $11 Million - $18.4 Million	280,911 Added 258.27%	389,677 $15.8 Million
Q3 2022 Nov 03, 2022	BUY	$61.1 - $83.78 $5.32 Million - $7.3 Million	87,117 Added 402.41%	108,766 $7.11 Million
Q2 2022 Aug 12, 2022	BUY	$43.23 - $73.83 $174,000 - $297,165	4,025 Added 22.84%	21,649 $1.32 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $183,665 - $273,615	3,453 Added 24.37%	17,624 $1.11 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $1.32 Million - $2.1 Million	-18,859 Reduced 57.1%	14,171 $1.07 Million
Q3 2021 Nov 09, 2021	BUY	$110.2 - $156.64 $1.32 Million - $1.88 Million	12,006 Added 57.11%	33,030 $3.7 Million
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $1.54 Million - $2.46 Million	15,224 Added 262.48%	21,024 $3.4 Million
Q1 2021 May 13, 2021	SELL	$110.72 - $210.04 $1.54 Million - $2.93 Million	-13,947 Reduced 70.63%	5,800 $706,000
Q4 2020 Feb 11, 2021	BUY	$79.67 - $173.23 $509,091 - $1.11 Million	6,390 Added 47.84%	19,747 $3.02 Million
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $1.04 Million - $1.33 Million	13,246 Added 11933.33%	13,357 $1.12 Million
Q2 2020 Aug 12, 2020	SELL	$38.5 - $76.05 $1,424 - $2,813	-37 Reduced 25.0%	111 $8,000
Q1 2020 May 13, 2020	SELL	$33.68 - $62.53 $173,822 - $322,717	-5,161 Reduced 97.21%	148 $6,000
Q4 2019 Feb 10, 2020	SELL	$36.68 - $73.13 $314,274 - $626,577	-8,568 Reduced 61.74%	5,309 $324,000
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $170,149 - $218,176	4,151 Added 42.68%	13,877 $568,000
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $179,837 - $244,518	-5,073 Reduced 34.28%	9,726 $459,000
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $277,958 - $405,430	9,920 Added 203.32%	14,799 $528,000
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $165,974 - $309,166	-7,302 Reduced 59.95%	4,879 $139,000
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $203,566 - $301,608	-4,590 Reduced 27.37%	12,181 $541,000
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $45,646 - $78,814	1,071 Added 6.82%	16,771 $985,000
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $9,408 - $23,268	400 Added 2.61%	15,700 $717,000
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $58,240 - $80,677	3,436 Added 28.96%	15,300 $360,000
Q3 2017 Nov 14, 2017	BUY	$16.75 - $20.66 $198,722 - $245,110	11,864	11,864 $211,000

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account